Track the 메타바이오메드 share price and the full management transaction log of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 메타바이오메드 has logged 37 reports. Market capitalisation: €104.7bn. The latest transaction was reported on 25 August 2026 (Purchase). Among the most active insiders: 오지수. The full history is openly available.
37
Insider Decl.
n/a
Thresholds
€1,687
28 ops.
Buy Volume
n/a
1 ops.
Sell Volume
15Σ signal
Buys €1,687n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,417 of 29,024 companies
65.5
score / 100
Value
68
Quality
64
FCF yld-0.6%
Earn yld10%
EV/EBITDA7.2x
ROE·
Gross mgn52%
Net mgn11%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Meta Biomed is a company listed on the XKRX market, specializing in the healthcare and pharmaceutical sector. It focuses on the development and commercialization of innovative solutions for the medical field.